AHR Launches Forward Stock Offering, Heightening Dilution Concerns

What happened

American Healthcare REIT announced a forward public offering of 14 million shares via BofA Securities, adding to its already sizable $1B ATM program. The move underscores the company's heavy reliance on equity capital to fund its acquisition-driven growth strategy. While management may frame the offering as accretive, the constant dilution weighs on per-share metrics, especially with the stock trading at a lofty 32x EV/EBITDA. This news validates the key risk outlined in our prior analysis: AHR's growth engine depends on continuous equity issuance, leaving little margin for error. If 2026 guidance disappoints or same-store NOI growth normalizes, the current premium valuation offers minimal downside protection.

Implication

The forward sale of 14 million shares, while potentially funding accretive deals, signals that AHR continues to tap equity to fuel growth, compounding dilution for existing holders. Given the stock's premium valuation (~32x EV/EBITDA), any deceleration in same-store NOI or NFFO growth could lead to multiple compression and significant downside. Investors should monitor the company's 2026 guidance for signs of growth normalization, as the dilution from this and prior offerings may mask underlying portfolio performance. In our base case, total returns over the next 12-18 months are likely to be sub-10%, with asymmetric downside risk. We recommend trimming into strength or waiting for a pullback toward our attractive entry of $40.

Thesis delta

The announcement of a forward offering confirms our thesis that AHR is structurally reliant on equity issuance to fund acquisitions, exacerbating dilution risk. This capital-raising event, while typical for AHR, adds pressure to per-share growth just as same-store NOI growth is expected to normalize. We see this as a negative signal that reinforces our Potential Sell rating and view of limited upside at current levels.